Von Willebrand factor: An emerging target in stroke therapy

Stroke

Volumn 43, Issue 2, 2012, Pages 599-606

  De Meyer, Simon F ^a,b,c,d   Stoll, Guido ^e   Wagner, Denisa D ^a,b,c   Kleinschnitz, Christoph ^e  

^a Immune Disease Institute   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

glycoprotein Ib; platelets; stroke; von Willebrand factor

Indexed keywords

AJW 200; ALX 0081; ALX 0681; ANTICOAGULANT AGENT; EGAPTIVON PEGOL; GPG 290; MONOCLONAL ANTIBODY 6B4 H6B4; MONOCLONAL ANTIBODY 82D6A3; RECOMBINANT VON WILLEBRAND FACTOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; DRUG TARGETING; HEMOSTASIS; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOEMBOLISM; THROMBOSIS;

ADAM PROTEINS; BLOOD PLATELETS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HUMANS; INFLAMMATION; INTRACRANIAL THROMBOSIS; STROKE; VON WILLEBRAND FACTOR;

EID: 84856475588     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.628867     Document Type: Article

References (86)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-1757. (Pubitemid 43767064)
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8:141-150.
4. Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM, Diener H-C, Howard G, et al. Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke. 2009;40:3796-3803.
5. Stoll G, Kleinschnitz C, Nieswandt B. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008;112:3555-3562.
6. von Willebrand EA. Hereditar pseudohemofili. Fin Laekaresaellsk Hand. 1926;68:87-112.
7. Wagner DD, Frenette PS. The vessel wall and its interactions. Blood. 2008;111:5271-5281.
8. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. Blood. 2009;113:5049-5057.
9. Pendu R, Terraube V, Christophe OD, Gahmberg CG, de Groot PG, Lenting PJ, et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood. 2006;108:3746-3752. (Pubitemid 44864554)
10. Bernardo A, Ball C, Nolasco L, Choi H, Moake JL, Dong JF. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3:562-570. (Pubitemid 41632882)
11. Petri B, Broermann A, Li H, Khandoga AG, Zarbock A, Krombach F, et al. von Willebrand factor promotes leukocyte extravasation. Blood. 2010; 116:4712-4719.
12. Pinsky DJ, Naka Y, Liao H, Oz MC, Wagner DD, Mayadas TN, et al. Hypoxia-induced exocytosis of endothelial cell Weibel-Palade bodies. A mechanism for rapid neutrophil recruitment after cardiac preservation. J Clin Invest. 1996;97:493-500.
13. Krishnan S, Siegel J, Pullen G, Hevelow M, Dampier C, Stuart M. Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia. Thromb Res. 2008;122:455-458.
14. Zhou Z, Nguyen TC, Guchhait P, Dong JF. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2010;36:71-81.
15. Lindblom A, Thorsen S, Hillarp A, Björk P. Minor stroke as singular manifestation of hereditary thrombotic thrombocytopenic purpura in a young man. Int Angiol. 2009;28:336-339.
16. Sevy A, Doche E, Squarcioni C, Poullin P, Serratrice J, Nicoli F, et al. Stroke in a young patient treated by alteplase heralding an acquired thrombotic thrombocytopenic purpura. J Clin Apheresis. 2011;26: 152-155.
17. Chauhan AK, Motto DG, Lamb CB, Bergmeier W, Dockal M, Plaimauer B, et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006;203:767-776.
18. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD. ADAMTS13: A new link between thrombosis and inflammation. J Exp Med. 2008;205:2065-2074.
19. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4:1186-1193.
20. Licata G, Tuttolomondo A, Di Raimondo D, Corrao S, Di Sciacca R, Pinto A. Immuno-inflammatory activation in acute cardio-embolic strokes in comparison with other subtypes of ischaemic stroke. Thromb Haemost. 2009;101:929-937.
21. Kozuka K, Kohriyama T, Nomura E, Ikeda J, Kajikawa H, Nakamura S. Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype. Atherosclerosis. 2002;161:161-168. (Pubitemid 34214832)
22. Bath PM, Blann A, Smith N, Butterworth RJ. von Willebrand factor, P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets. 1998;9:155-159. (Pubitemid 28312672)
23. Stott DJ, Spilg E, Campbell AM, Rumley A, Mansoor MA, Lowe GD. Haemostasis in ischaemic stroke and vascular dementia. Blood Coagul Fibrinolysis. 2001;12:651-657. (Pubitemid 33139684)
24. Lip GYH, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: the West Birmingham Stroke Project. Blood Coagul Fibrinolysis. 2002;13:339-347. (Pubitemid 35001875)
25. Bongers TN, de Bruijne ELE, Dippel DWJ, de Jong AJ, Deckers JW, Poldermans D, et al. Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. Atherosclerosis. 2009;207: 250-254.
26. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ. von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality. Thromb Haemost. 1997;77: 1104-1108. (Pubitemid 27311977)
27. Qizilbash N, Duffy S, Prentice CR, Boothby M, Warlow C. von Willebrand factor and risk of ischemic stroke. Neurology. 1997;49:1552-1556. (Pubitemid 28015116)
28. Bongers TN, de Maat MPM, van Goor M-LPJ, Bhagwanbali V, van Vliet HHDM, Gómez García EB, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006;37:2672-2677. (Pubitemid 44922524)
29. Hanson E, Jood K, Karlsson S, Nilsson S, Blomstrand C, Jern C. Plasma levels of von Willebrand factor in the etiologic subtypes of ischemic stroke. J Thromb Haemost. 2011;9:275-281.
30. van Schie MC, De Maat MPM, Dippel DWJ, de Groot PG, Lenting PJ, Leebeek FWG, et al. von Willebrand factor propeptide and the occurrence of a first ischemic stroke. J Thromb Haemost. 2010;8:1424-1426.
31. Wieberdink RG, van Schie MC, Koudstaal PJ, Hofman A, Witteman JCM, de Maat MPM, et al. High von Willebrand factor levels increase the risk of stroke. The Rotterdam Study. Stroke. 2010;41:2151-2156.
32. Roldán V, Marín F, García-Herola A, Lip GYH. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation. Thromb Res. 2005;116:321-325. (Pubitemid 40994915)
33. Lip GYH, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke. 2006;37:2294-2300. (Pubitemid 44337172)
34. Pinto A, Tuttolomondo A, Casuccio A, Di Raimondo D, Di Sciacca R, Arnao V, et al. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci. 2009;116:781-789.
35. Conway DSG, Pearce LA, Chin BSP, Hart RG, Lip GYH. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation. 2003;107:3141-3145. (Pubitemid 36793082)
36. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. 2007;115:2119-2127. (Pubitemid 46659063)
37. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation. 1999;100:736-742. (Pubitemid 29383644)
38. Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007;38: 1873-1880. (Pubitemid 46847262)
39. van Schie MC, de Maat MPM, Isaacs A, van Duijn CM, Deckers JW, Dippel DWJ, et al. Variation in the von Willebrand factor gene is associated with vWF levels and with the risk of cardiovascular disease. Blood. 2011;117:1393-1399.
40. Dai K, Gao W, Ruan C. The SMA I polymorphism in the von Willebrand factor gene associated with acute ischemic stroke. Thromb Res. 2001; 104:389-395. (Pubitemid 34084805)
41. van Schie MC, van Loon JE, de Maat MP, Leebeek FW. Genetic determinants of von Willebrand factor levels and activity in relation to the risk of cardiovascular disease. A review. J Thromb Haemost. 2011;9: 899-908.
42. Hanson E, Jood K, Nilsson S, Blomstrand C, Jern C. Association between genetic variation at the ADAMTS13 locus and ischemic stroke. J Thromb Haemost. 2009;7:2147-2148.
43. Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Culleré M, Hynes RO, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA. 1998;95: 9524-9529. (Pubitemid 28506264)
44. De Meyer SF, Schwarz T, Deckmyn H, Denis CV, Nieswandt B, Stoll G, et al. Binding of von Willebrand factor to collagen and glycoprotein Ibalpha, but not to glycoprotein IIb/IIIa, contributes to ischemic stroke in mice. Arterioscler Thromb Vasc Biol. 2010;30:1949-1951.
45. Kleinschnitz C, De Meyer SF, Schwarz T, Austinat M, Vanhoorelbeke K, Nieswandt B, et al. Deficiency of von Willebrand factor protects mice from ischemic stroke. Blood. 2009;113:3600-3603.
46. Zhao B-Q, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M, et al. von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood. 2009;114:3329-3334.
47. De Meyer SF, Vandeputte N, Pareyn I, Petrus I, Lenting PJ, Chuah MKL, et al. Restoration of plasma von Willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von Willebrand disease. Arterioscler Thromb Vasc Biol. 2008;28:1621-1626.
48. Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Köllnberger M, et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 2011;117:1400-1407.
49. Chauhan AK, Kisucka J, Lamb CB, Bergmeier W, Wagner DD. von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins. Blood. 2007;109:2424-2429. (Pubitemid 46425884)
50. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106: 385-392. (Pubitemid 30655638)
51. Fujioka M, Hayakawa K, Mishima K, Kunizawa A, Irie K, Higuchi S, et al. ADAMTS13 gene deletion aggravates ischemic brain damage: A possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood. 2010;115:1650-1653.
52. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation. 2007;115:2323-2330. (Pubitemid 46685900)
53. Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. Blood. 2002;100: 2102-2107. (Pubitemid 35001244)
54. Elvers M, Stegner D, Hagedorn I, Kleinschnitz C, Braun A, Kuijpers MEJ, et al. Impaired alpha(IIb)beta(3) integrin activation and sheardependent thrombus formation in mice lacking phospholipase D1. Sci Signal. 2010;3:ra1.
55. De Meyer SF, Schwarz T, Schatzberg D, Wagner DD. Platelet glycoprotein lbαis an important mediator of ischemic stroke in mice. Exp Transl Stroke Med. 2011;3:9.
56. De Meyer SF, De Maeyer B, Deckmyn H, Vanhoorelbeke K. von Willebrand factor: drug and drug target. Cardiovasc Hematol Disord Drug Targets. 2009;9:9-20.
57. De Meyer SF, Vanhoorelbeke K, Ulrichts H, Staelens S, Feys HB, Salles I, et al. Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs. Cardiovasc Hematol Disord Drug Targets. 2006;6:191-207. (Pubitemid 44377772)
58. Firbas C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther. 2010;8: 1689-1701.
59. Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, Depraetere H, Kotze HF, et al. Inhibition of the von Willebrand (vWF)-collagen interaction by an antihuman vWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood. 2002;99: 3623-3628. (Pubitemid 34534531)
60. Staelens S, Desmet J, Ngo TH, Vauterin S, Pareyn I, Barbeaux P, et al. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol Immunol. 2006;43:1243-1257. (Pubitemid 43063177)
61. Kageyama S, Yamamoto H, Nagano M, Arisaka H, Kayahara T, Yoshimoto R. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol. 1997;122:165-171. (Pubitemid 27376034)
62. Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res. 2001;101:395-404. (Pubitemid 32280850)
63. Kageyama S, Yamamoto H, Yoshimoto R. Anti-human von Willebrand factor monoclonal antibody AJvW-2 prevents thrombus deposition and neointima formation after balloon injury in guinea pigs. Arterioscler Thromb Vasc Biol. 2000;20:2303-2308.
64. Cauwenberghs N, Meiring M, Vauterin S, van Wyk V, Lamprecht S, Roodt JP, et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol. 2000;20:1347-1353. (Pubitemid 30262938)
65. Fontayne A, Meiring M, Lamprecht S, Roodt J, Demarsin E, Barbeaux P, et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb Haemost. 2008;100:670-677.
66. Fontayne A, Vanhoorelbeke K, Pareyn I, Van Rompaey I, Meiring M, Lamprecht S, et al. Rational humanization of the powerful antithrombotic anti-GPIbalpha antibody: 6B4. Thromb Haemost. 2006;96:671-684. (Pubitemid 44782549)
67. Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol. 2002;22:323-328. (Pubitemid 34127047)
68. Kageyama S, Yamamoto H, Nakazawa H, Matsushita J, Kouyama T, Gonsho A, et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol. 2002;22:187-192. (Pubitemid 34076252)
69. Machin SJ, Clarke C, Ikemura O, Kageyama S, Mackie IJ, Talbot JA, et al. A humanized monoclonal antibody against vWF A1 domain inhibits vWF:RiCof activity and platelet adhesion in human volunteers. J Thromb Haemost. 2003;1:Abstract OC328.
70. Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, et al. Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis. Thromb Haemost. 2006;95: 469-475.
71. Wadanoli M, Sako D, Shaw GD, Schaub RG, Wang Q, Tchernychev B, et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost. 2007;98:397-405. (Pubitemid 47260291)
72. Keefe AD, Schaub RG. Aptamers as candidate therapeutics for cardiovascular indications. Curr Opin Pharmacol. 2008;8:147-152.
73. Diener JL, Daniel Lagassé HA, Duerschmied D, Merhi Y, Tanguay J-F, Hutabarat R, et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost. 2009;7:1155-1162.
74. Rottman JB, Gilbert M, Marsh HN, Boomer RM, Fraone JM, Makim A, et al. An anti-von Willebrand's factor A1 domain aptamer inhibits arterial thrombosis induced by electrical injury in cynomolgus macaques. J Thromb Haemost. 2007;5:Abstract P-S-664.
75. Cataland SR, Peyvandi F, Mannucci PM, Lammle B, Hovinga JAK, Machin SJ, et al. A randomized, double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura (TTP). Blood. 2010;116:Abstract 726.
76. Jilma-Stohlawetz P, Gorczyca ME, Jilma B, Siller-Matula J, Gilbert JC, Knöbl P. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura. Thromb Haemost. 2011;105:545-552.
77. Knöbl P, Jilma B, Gilbert JC, Hutabarat RM, Wagner PG, Jilma-Stohlawetz P. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion. 2009;49: 2181-2185.
78. Jilma B, Paulinska P, Jilma-Stohlawetz P, Gilbert JC, Hutabarat R, Knöbl P. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease. Thromb Haemost. 2010;104:563-570.
79. Woelfel M, De Meyer SF, Wagner P, McGinness KE, Wagner DD, Schaub R. The generation of an aptamer inhibitor of murine von Willebrand factor (vWF) mediated platelet aggregation. Blood. 2010;116: Abstract 4312.
80. Markus HS, McCollum C, Imray C, Goulder MA, Gilbert J, King A. The von Willebrand inhibitor ARC1779 reduces cerebral embolization after carotid endarterectomy: A randomized trial. Stroke. 2011;42:2149-2153.
81. Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared to currently marketed antiplatelet drugs. Blood. 2011;118:757-765.
82. van Loon JE, de Jaegere PP, Ulrichts H, van Vliet HH, de Maat MP, de Groot PG, et al. The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thromb Haemost. 2011;106:165-171.
83. Kidwell CS, Saver JL, Starkman S, Duckwiler G, Jahan R, Vespa P, et al. Late secondary ischemic injury in patients receiving intraarterial thrombolysis. Ann Neurol. 2002;52:698-703. (Pubitemid 35403178)
84. del Zoppo GJ, Koziol JA. Recanalization and stroke outcome. Circulation. 2007;115:2602-2605. (Pubitemid 46791357)
85. Sandercock PA, Counsell C, Kamal AK. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;4:CD000024.
86. Adams HP, Jr., del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.